Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

2.

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE.

Biol Blood Marrow Transplant. 2002;8(8):435-43.

PMID:
12234169
4.

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ.

Blood. 2007 Jul 1;110(1):409-17. Epub 2007 Mar 20.

5.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R; EORTC and GIMEMA Leukemia Groups.

Blood. 2003 Aug 15;102(4):1232-40. Epub 2003 Apr 24.

6.

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B.

Blood. 2007 May 1;109(9):3658-66. Epub 2007 Jan 9.

7.

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.

Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S, Ohno R.

Int J Hematol. 2010 Mar;91(2):284-92. doi: 10.1007/s12185-009-0483-2.

PMID:
20063133
8.

Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.

Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB.

Ann Hematol. 2005 Jan;84(1):25-32. Epub 2004 Sep 3.

PMID:
15349754
9.

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.

Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, Hartmann F, Horst HA, Koller E, Petzer A, Grimminger W, Kobbe G, Glasmacher A, Salwender H, Kirchen H, Haase D, Kremers S, Matzdorff A, Benner A, Döhner H.

J Clin Oncol. 2010 Oct 20;28(30):4642-8. doi: 10.1200/JCO.2010.28.6856. Epub 2010 Aug 30.

10.

Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.

Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, Pomponio G, Martinelli G, Isidori A, Sparaventi G, Leoni P.

Leuk Lymphoma. 2006 Jun;47(6):1091-102.

PMID:
16840201
11.

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.

Eur J Haematol. 2009 Aug;83(2):99-107. doi: 10.1111/j.1600-0609.2009.01256.x. Epub 2009 Apr 6.

PMID:
19385987
12.

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.

Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D.

J Clin Oncol. 2005 Oct 20;23(30):7676-84. Epub 2005 Sep 26.

14.

[Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].

Xu LP, Huang XJ, Liu KY, Chen H, Liu DH, Zhang YC, Chen YH, Han W, Gao ZY, Lu DP.

Beijing Da Xue Xue Bao. 2005 Jun 18;37(3):231-5. Chinese.

16.

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H.

Blood. 2002 May 15;99(10):3517-23.

17.

Postremission therapy for acute myeloid leukemia in the first remission.

Kim ST, Jung CW, Lee J, Kwon JM, Oh SY, Park BB, Lee HR, Kim HJ, Kim K, Kim WS, Ahn JS, Kang WK, Park K.

Leuk Lymphoma. 2007 May;48(5):937-43.

PMID:
17487738
18.

Acute myeloid leukemia: when to transplant in first complete remission.

Hill BT, Copelan EA.

Curr Hematol Malig Rep. 2010 Apr;5(2):101-8. doi: 10.1007/s11899-010-0042-1. Review.

PMID:
20425403
19.

Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.

Auberger J, Clausen J, Willenbacher W, Erdel M, Gunsilius E, Petzer A, Gastl G, Nachbaur D.

Int J Hematol. 2008 May;87(4):382-6. doi: 10.1007/s12185-008-0084-5.

PMID:
18418698
20.

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M, Creutzig U, Klingebiel T.

Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.

Items per page

Supplemental Content

Write to the Help Desk